Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Maria Dolores Mediano Rambla


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


M.D. Mediano Rambla1, J.A. Marcos2, R. Carrillo1, M. espinosa1, F. Sanchez3, M.D. alvardado2, L. Rendon2, J.J. Reina Zoilo4, A. albero1

Author affiliations

  • 1 Medical Oncology Unit, Hospital Universitario Virgen Macaren, 41009 - Sevilla/ES
  • 2 Clinical Pharmacology, Hospital Universitario Virgen Macaren, 41009 - Sevilla/ES
  • 3 Biochemistry, Hospital Universitario Virgen Macaren, 41009 - Sevilla/ES
  • 4 Medical Oncology Dt, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5074


Severe toxicity as a result of Fluoropyrimidine treatments appears in up 30% of patients. The reduce activity of DPD is one of the main cause of severe adverse events. Up to 8% of the population have low levels of DPD, and up to 0.5% of the population completely lack the enzyme. We assessed the effect of prospective screening for the 4 most relevant variants (DPYD*2A [rs3918290, c.1905 + 1G>A, IVS14 + 1G>A], c.2846A>T [rs67376798, D949V], c.1679T>G [rs55886062, DPYD*13, I560S], c.1236G>A [rs56038477, E412E, in haplotype B3]) and rs34743033 TYMS, on patient safety and dose individualization in daily clinical practice.


We described our experience in a Tertiary University Hospital. We reviewed 208 patients with gastrointestinal cancer who were planned to receive fluoropyrimide treatment and we did prospective genotyping for DPYD*2A, c.2846A>T, c.1679T>G, c.1236G>A and rs34743033 TYMS. Heterozygous DPD variant allele carriers received an initial dose reduction of 25% (c.2846A>T and c.1236G>A) or 50% (DPYD*2A and c.1679T>G), and DPYD wild-type patients were treated according to the current standard of care.


From April 2017 to March 2019, 208 patients were pre-tested. 8 patients (3´8%) were heterozygous DPD variant allele carriers and 200 (96´2%) were DPD wild-type patients. Overall, fluoropyrimidine-related severe toxicity was higher in DPD variant carriers (2 [25%] of 8 patients) than in wild-type patients (70 [35%] of 200 patients). 2 patients with c.1236G>A and rs34743033 TYMS heterozygous were necessary to disrupt treatment in spite of dose reduction because of severe diarrhea. However, the other 6 heterozygous have low grade toxicity with reduction preplanned.


Life-threatening toxicities could be presented in patients with DPD deficiency if they are treated with standar dose of fluoropyridimes. Last colorectal cancer ESMO guidelines do not recommend testing DPD deficient up front. It recommend in case of patients who experience severe toxicity, DPD levels should be tested before 5-FU is re-introduced. We suggest due to our control of potential toxicities that implementation of DPD genotype individualised dosing should be a new standard of care.

Legal entity responsible for the study: Mediano Rambla.

Clinical trial identification

Editorial acknowledgement


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.